Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LAM focuses on Chinese diabetic ulcer market:

This article was originally published in Clinica

Executive Summary

LAM Pharmaceutical is to explore distribution and strategic alliance opportunities in China with Benchmark Global Capital Group's Chinese subsidiary, one of the leading US-based investment and consulting firms in China. Lewiston, New York-based LAM develops the IPM wound gel, for the management of certain skin ulcers and wounds. Benchmark notes that, although China has the world's largest diabetic population, with almost 65 million patients, there are currently no effective products for treating diabetic wounds and ulcers on the Chinese market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel